Hope you we'nt referring to my post Mac--Thats about as fundamental as it gets---(ok -TAs not looking to bad as well:)
Printable View
It was someone else that brought it to my attention.
If you dont think the fundamentals are good compared to PEB--thats fine.
Ive just noticed that its easy to get so wrapped up in one share that its possible to lose perspective.
Not sure where your going with the condoms but Im not suggesting everyone sell--but it cant hurt to keep our eyes open.
Just why is it that you believe PEB is undervalued?
Their goal is 100mil in 5yrs--NAN 300mil and in terms of market --its global--its cash flow positive and soon to be profitable.
I realize that a fair number have alot more invested than just money--but just giving another perspective----Ive looked at them side by side and for me ,it was no contest.---doesnt mean for sure you wont have the last laugh(tinged with bitterness?) Best of Luck
Disc-Its of no advantage to me if the SP drops--my ''spec'' $ is all invested (only keep a small % for this sort of thing)
The AGM presentations by NAN (Nanosonics) are worth going through for PEB investors and shareholders.
PEB talks about the 'J' curve in its revenues and earnings profile, and NAN is an excellent example of the 'J' curve at play.
Whether PEB will do a 'J' curve will not be known until 2017/18.
Certainly the Australian market was not prepared to re-rate NAN until there were clear indicators of growth in revenues and cashflow.
PEB has the benefit of relatively inexperienced NZ investors (few biomed companies in NZ) and shareholders imo who are rating the company on promises.
Talking of J-curves here's my version
Forecasts based on the promise of $100m in sales in 5 years and my estimates as to what that costs to achieve. No other rationale than that. I only did a DCF to see what it might be worth if promise delivered.
Great looking chart eh
Even so at 12% discount rate I only come up with 94 cents .... 15% discount rate only 63 cents
But then again from what Pacific Edge are talking about we should construct a series of J-curves .... one for each for the new products
Medtech apples and biotech oranges.
You may say the value proposition is different, and biotech is a much higher risk, higher reward game.
https://atpbio.wordpress.com/2011/09...-from-medtech/
Chief executive David Darling said while the company's US lab could handle 260,000 tests at present, it could be expanded to meet the opportunity of two million tests.
''It's the scale and accessibility which is paramount to success,'' he said.
http://www.odt.co.nz/news/business/3...old-be-patient
J-curves are often used to represent how private equity cash flows develop
Initial up front cash to buy businesses and then a bit more to fix them in various ways and then the big pay day when they sell / IPO them.
PEB J-curve from an investors perspective maybe the takeover/merger is the big payday. Still believe this is best outcome for investors.
Not that much over a $1 would be a 400% plus return .....who could complain about that?